Therese Liechtenstein

Therese Liechtenstein is the Investment Director at 4BIO Capital, where she leads investments in early-stage therapeutics and emerging biotechnology companies. Prior to joining this firm, she worked at M Ventures, the corporate venture capital arm of Merck KGaA, managing strategic healthcare projects for the organization's global business. Her academic credentials include a PhD in Immuno-Oncology from University College London, which directly informs her technical evaluation of complex medical startups. Furthermore, she earned a Master of Science in Biomedical Sciences, as well as a Bachelor of Arts in Biology and Business from New York University. She has also contributed to industry research, including a 2022 publication analyzing the future trajectory of global fertility care markets. Liechtenstein currently focuses on utilizing her specialized scientific background and corporate venture experience to scale early-stage immuno-oncology and therapeutic ventures.